Rare Disease Report
Patients & Caregivers


Jim Palma sits down with RDR to discuss cholangiocarcinoma, the disease with which Paul Poth, his brother-in-law and the founder of TargetCancer, was diagnosed.
Almost 3 years since its approval to treat patients with neuroendocrine tumors, Somatuline Depot has received a supplemental indication to treat carcinoid syndrome.
Accelerated Approval was granted to Bayer Healthcare Pharmaceuticals’ Aliqopa (copanlisib) today for the treatment of follicular lymphoma.
Amgen’s Mvasi (bevacizumab-awwb), a biosimilar to Avastin, is now FDA-approved for use in adults to treat multiple types of cancer.
Daiichi Sankyo and MD Anderson Cancer Center announced a multi-year collaboration dedicated to accelerating the development of novel therapies to treat AML.
A study led by oncologists at the Children’s Hospital of Philadelphia discovered a new target that could lead to the treatment and prevention of neuroblastoma.
Clinical data reveals that X4P-001-IO with Inlyta demonstrated encouraging disease control rates and durable responses in clear cell renal cell carcinoma.
Two clinical trials published in NEJM  show Opdivo (nivolumab) to be the superior drug.
A knife can be both a weapon and a tool; it depends on why you are using it. The same may also apply to the Zika virus.
Data presented at the ESMO Annual Meeting shows that Erytech's eyraspase could potentially be an effective treatment in patients with pancreatic adenocarcinoma.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.